Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMbrave152 in untreated advanced or metastatic hepatocellular carcinoma
PACTR202405856204528Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Atezolizumab plus bevacizumab plus tiragolumab with Atezolizumab plus bevacizumab plus placebo (2 arms). Planned start May 2024; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumabtiragolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on PACTR202405856204528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405856204528.